» Articles » PMID: 9445477

Protein Kinase B Kinases That Mediate Phosphatidylinositol 3,4,5-trisphosphate-dependent Activation of Protein Kinase B

Overview
Journal Science
Specialty Science
Date 1998 Feb 21
PMID 9445477
Citations 339
Authors
Affiliations
Soon will be listed here.
Abstract

Protein kinase B (PKB) is activated in response to phosphoinositide 3-kinases and their lipid products phosphatidylinositol 3,4, 5-trisphosphate [PtdIns(3,4,5)P3] and PtdIns(3,4)P2 in the signaling pathways used by a wide variety of growth factors, antigens, and inflammatory stimuli. PKB is a direct target of these lipids, but this regulation is complex. The lipids can bind to the pleckstrin homologous domain of PKB, causing its translocation to the membrane, and also enable upstream, Thr308-directed kinases to phosphorylate and activate PKB. Four isoforms of these PKB kinases were purified from sheep brain. They bound PtdIns(3,4,5)P3 and associated with lipid vesicles containing it. These kinases contain an NH2-terminal catalytic domain and a COOH-terminal pleckstrin homologous domain, and their heterologous expression augments receptor activation of PKB, which suggests they are the primary signal transducers that enable PtdIns(3,4,5)P3 or PtdIns- (3,4)P2 to activate PKB and hence to control signaling pathways regulating cell survival, glucose uptake, and glycogen metabolism.

Citing Articles

Mammalian mitochondrial inorganic polyphosphate (polyP) and cell signaling: Crosstalk between polyP and the activity of AMPK.

Da Costa R, Nichenko A, Perez M, Tokarska-Schlattner M, Kavehmoghaddam S, Hambardikar V Mol Metab. 2024; 91:102077.

PMID: 39617267 PMC: 11696858. DOI: 10.1016/j.molmet.2024.102077.


Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.

Lyu C, Vaddi P, Elshafae S, Pradeep A, Ma D, Chen S Oncogene. 2024; 44(5):322-335.

PMID: 39537875 DOI: 10.1038/s41388-024-03224-9.


Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.

Wang K, Chen M, Yan S, Han Y, Yuan H, Liu Q Oncogene. 2024; 44(1):8-18.

PMID: 39438763 DOI: 10.1038/s41388-024-03195-x.


Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.

Willis B, Mongeon K, Dry H, Neveras I, Bryan N, Pandya M Leukemia. 2024; 38(12):2663-2674.

PMID: 39284898 PMC: 11588655. DOI: 10.1038/s41375-024-02401-9.


mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma.

Mei L, Sun H, Yan Y, Ji H, Su Q, Chang L Int J Biol Sci. 2024; 20(11):4178-4189.

PMID: 39247820 PMC: 11379076. DOI: 10.7150/ijbs.95894.